About Ornithine aminotransferase, mitochondrial
Ornithine aminotransferase, mitochondrial (OAT) is a protein
from Homo sapiens identified by UniProt accession
P04181, 439 residues long.
MolForge cross-references it against 0 known binders and
327 disease associations.
Target properties
| Protein name | Ornithine aminotransferase, mitochondrial |
| UniProt accession | P04181 |
| Gene | OAT |
| Organism | Homo sapiens |
| Length | 439 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (327)
Diseases linked to this target (Open Targets).
- ornithine aminotransferase deficiency · score 0.85
- Gyrate atrophy of choroid and retina · score 0.81
- Retinal dystrophy · score 0.36
- optic atrophy · score 0.27
- Visual field defect · score 0.27
- pain · score 0.27
- Abnormal choroid morphology · score 0.27
- arterial stiffness measurement · score 0.26
- proctitis · score 0.21
- ulcer disease · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P04181-F1 | alphafold | PREDICTED | 94.08 | — |
Amino-acid sequence (439 residues)
MFSKLAHLQR FAVLSRGVHS SVASATSVAT KKTVQGPPTS DDIFEREYKY GAHNYHPLPV ALERGKGIYL WDVEGRKYFD FLSSYSAVNQ GHCHPKIVNA LKSQVDKLTL TSRAFYNNVL GEYEEYITKL FNYHKVLPMN TGVEAGETAC KLARKWGYTV KGIQKYKAKI VFAAGNFWGR TLSAISSSTD PTSYDGFGPF MPGFDIIPYN DLPALERALQ DPNVAAFMVE PIQGEAGVVV PDPGYLMGVR ELCTRHQVLF IADEIQTGLA RTGRWLAVDY ENVRPDIVLL GKALSGGLYP VSAVLCDDDI MLTIKPGEHG STYGGNPLGC RVAIAALEVL EEENLAENAD KLGIILRNEL MKLPSDVVTA VRGKGLLNAI VIKETKDWDA WKVCLRLRDN GLLAKPTHGD IIRFAPPLVI KEDELRESIE IINKTILSF
Explore Ornithine aminotransferase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets